CYCN
CyclerionยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CYCN Profile
Cyclerion Therapeutics, Inc.
A clinical-stage biopharmaceutical company that develops and commercializes treatments for serious and orphan diseases
245 First Street, 18th Floor, Cambridge, Massachusetts 02142
--
Cyclerion Therapeutics, Inc., was incorporated in Massachusetts on September 6, 2018. Cyclerion is a biopharmaceutical company focused on the use of novel soluble guanylate cyclase stimulators in the central nervous system and peripheral for the treatment of serious diseases. The nitric oxide sGC cyclic guanosine monophosphate signaling pathway is the fundamental mechanism for precise control of key aspects of systemic physiology. The NO-SGC-cGMP pathway regulates a variety of key biological functions of the CNS and the periphery and has been successfully targeted by several drugs.
